Abstract
Get full access to this article
View all access options for this article.
References
1.
June
CH
and
M
Sadelain
. (2018 ). Chimeric antigen receptor therapy . N Engl J Med , 379 :64 –73 .
2.
Pickar
AK
and
CA
Gersbach
. (2018 ). Gene therapies for hemophilia hit the mark in clinical trials . Nat Med , 24 :121 –122 .
3.(2018) . FDA approves hereditary blindness gene therapy . Nat Biotechnol , 36 :6 . https://doi.org/10.1038/nbt0118-6a
4.
Haapaniemi
E
,
Botla
S
,
J
Persson
,
Schmierer
B
and
Taipale.
J
(2018 ). CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response . Nat Med , 24 :927 –930 .
5.
Ihry
RJ
,
KA
Worringer
,
MR
Salick
,
E
Frias
,
D
Ho
,
K
Theriault
,
S
Kommineni
,
J
Chen
,
M
Sondey
, et al . (2018 ). p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells . Nat Med , 24 :939 –946 .
6.
Mlambo
T
,
Nitsch
S
,
Hildenbeutel
M
,
Romito
M
,
Muller
M
,
Bossen
C
,
Diederichs
S
,
Cornu
TI
,
Cathomen
T
and
Mussolino.
C
(2018 ). Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells . Nucleic Acids Res , 46 :4456 –4468 .